Introduction
Stem cell exhaustion and declining regenerative capacity are closely associated with aging and age-related diseases. Although stem cell-based interventions have shown promise for restoring tissue function, their application to aging remains challenging because of incomplete understanding of their mechanisms of action, complex in vivo behavior, limited engraftment efficiency, and potential tumorigenic risks.
In a study published in Cell, Lei J. and colleagues from the Institute of Zoology, Chinese Academy of Sciences, in collaboration with Xuanwu Hospital, Capital Medical University, developed senescence-resistant human mesenchymal progenitor cells (SRCs) engineered for enhanced resistance to senescence, environmental stress, and tumorigenic transformation. The study evaluated FOXO3-enhanced SRCs in aged cynomolgus monkeys and found that SRC treatment improved multiple features of systemic aging without inducing adverse events.
Importantly, exosome proteomics provided mechanistic insight into how SRCs exert their anti-aging effects, identifying 4,506 exosomal proteins enriched in antioxidant, anti-inflammatory, and innate immune regulatory factors. PTM BIO provided exosome proteomics technology support for this investigation.
Research Discovery
Engineering Stem Cells for Enhanced Anti-Aging Properties
The research team has spent more than a decade developing engineered long-lived cell systems. Earlier work established precise genetic correction strategies in human pluripotent stem cells, providing a foundation for engineering cells with enhanced longevity-related properties.
Building on this framework, the researchers developed two generations of senescence-resistant cell engineering strategies. SRC 1.0 targeted the oxidative stress regulatory hub NRF2 to strengthen antioxidant defenses, whereas SRC 2.0 introduced dual-site engineering of the longevity-associated gene FOXO3.
Systematic phenotypic characterization showed that FOXO3-enhanced SRCs exhibited strong resistance to senescence and environmental stress, together with favorable safety characteristics. These properties enabled the engineered progenitor cells to withstand aging-associated microenvironmental stress while reducing concerns related to tumorigenic transformation.
SRC Treatment Counteracts Multi-Organ Aging in Primates
The therapeutic potential of FOXO3-enhanced SRCs was subsequently evaluated in aged cynomolgus monkeys, corresponding approximately to humans in their 60s–70s. Following 44 weeks of SRC intervention, the treated animals showed improvements across multiple aging-associated phenotypes.
Continuous SRC treatment reduced the accumulation of senescent cells in multiple organs and suppressed inflammatory responses. The intervention was also associated with improvements in cognitive and reproductive functions, enhanced genomic stability, reduced oxidative stress, and restoration of protein homeostasis.
Transcriptomic analyses further indicated that SRC transplantation shifted aging-associated gene expression networks toward a younger state across more than half of the tissues examined. Aging-clock analyses estimated reductions in biological age of approximately 6–7 years for immature neurons and 5 years for oocytes.
Importantly, the study did not observe treatment-related adverse events, while histopathological analyses provided evidence supporting the safety and immune tolerance of SRC transplantation in the non-human primate model.
Exosome Proteomics Links SRCs to Anti-Aging Signaling
A central question was how transplanted SRCs could produce systemic effects across multiple tissues. Because extracellular vesicles, particularly exosomes, play important roles in intercellular communication and tissue repair, the researchers investigated the protein cargo released by SRCs.
Using exosome proteomics, the study identified 4,506 exosomal proteins. The identified cargo was enriched in proteins associated with antioxidant activity, inflammatory regulation, and innate immune responses.
These findings support a model in which SRC-derived exosomes act as important carriers of anti-aging signals. Rather than relying solely on direct cell replacement or engraftment, SRCs may influence distant tissues through extracellular vesicle-mediated molecular communication, contributing to cellular rejuvenation, suppression of chronic inflammation, and maintenance of genomic and epigenomic stability.
PTM BIO Technology Contribution
Addressing Key Technical Challenges
Understanding the paracrine and systemic effects of engineered stem cells requires comprehensive characterization of extracellular vesicle cargo. Exosomes contain diverse proteins that can collectively influence recipient cells, making unbiased protein profiling particularly valuable for identifying potential functional components.
In this study, PTM BIO provided exosome proteomics technology support, enabling systematic characterization of proteins carried by SRC-derived exosomes. This approach helped connect the engineered cell phenotype with its extracellular molecular output and provided molecular-level evidence for the role of exosomes in SRC-mediated anti-aging effects.
Advanced Proteomics Enables Critical Discovery
The exosome proteomics analysis identified 4,506 proteins in SRC-derived extracellular vesicles. Rather than focusing on a small number of predefined candidates, comprehensive protein profiling enabled the researchers to examine the functional composition of the exosomal cargo.
The detected proteins showed enrichment in pathways and functional categories related to:
Antioxidant responses
Inflammatory regulation
Innate immune regulation
Cellular and tissue homeostasis
This proteomic landscape provided an important molecular basis for interpreting the systemic effects observed following SRC transplantation.
The findings also demonstrate the value of extracellular vesicle proteomics in engineered cell therapy research. By profiling the molecular cargo released by therapeutic cells, researchers can move beyond evaluating cellular phenotypes alone and investigate the signaling molecules potentially responsible for downstream biological effects.
From Discovery Data to Biological Mechanism
The proteomics findings were integrated with the broader multi-organ aging analyses to establish a mechanistic framework for SRC-mediated aging intervention.
The study showed that SRC treatment was associated with reduced senescent cell accumulation, lower inflammatory activity, improved oxidative stress responses, enhanced genomic stability, and restoration of protein homeostasis across multiple tissues. The exosome proteome further revealed a cargo enriched in proteins related to antioxidant, anti-inflammatory, and innate immune functions.
Together, these observations support the concept that SRC-derived exosomes contribute to systemic anti-aging activity through intercellular molecular communication.
This connection is particularly important for understanding cell-based aging interventions: the therapeutic effects of engineered progenitor cells may extend beyond the transplanted cells themselves, with extracellular vesicles serving as molecular carriers that communicate beneficial signals to recipient tissues.
Scientific Impact
This study provides an experimental framework for developing engineered stem cell-based strategies against systemic aging. By combining FOXO3-based cell engineering, long-term intervention in aged non-human primates, multi-organ phenotyping, and exosome proteomics, the researchers demonstrated that senescence-resistant progenitor cells can influence multiple dimensions of organismal aging.
The identification of 4,506 exosomal proteins provides a broad molecular resource for investigating the extracellular mechanisms underlying these effects. In particular, the enrichment of antioxidant, anti-inflammatory, and innate immune regulatory proteins supports a potential role for SRC-derived exosomes in maintaining cellular and tissue homeostasis during aging.
More broadly, the work highlights extracellular vesicle proteomics as an important tool for connecting engineered cell phenotypes with their paracrine functions. It may also provide a foundation for future investigation of cell-free components derived from engineered cells in aging and regenerative medicine.
PTM BIO
PTM BIO provides integrated proteomics and post-translational modification (PTM) proteomics solutions for biomedical research, supporting discovery from protein identification and quantification to pathway analysis and mechanistic interpretation.
Our technology portfolio covers 4D proteomics, 10X proteomics, quantitative and targeted proteomics, PTM proteomics, phosphoproteomics, spatial proteomics, and single-cell proteomics, together with customized analytical strategies for complex biological samples.
For extracellular vesicle and exosome research, proteomics enables comprehensive characterization of protein cargo and helps researchers investigate cell-cell communication, disease mechanisms, therapeutic responses, and biomarker candidates. By combining advanced mass spectrometry with integrated bioinformatics, PTM BIO supports researchers in translating complex proteomic datasets into biologically meaningful insights.
Through close scientific collaboration, PTM BIO aims to provide reliable, high-quality proteomics solutions that accelerate discovery across aging research, stem cell biology, regenerative medicine, and translational research.
